Idanuz

Icatibant, the active ingredient in Idanuz, is a bradykinin B2 receptor antagonist presented as a sterile solution for subcutaneous injection use. It treats acute hereditary angioedema attacks in patients with type I or type II HAE. The drug is indicated for patients aged 12 years and older and is administered by a single subcutaneous injection at the onset of an attack.

GNH USA supplies Idanuz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and timely delivery across multiple regions.

Icatibant is used to treat hereditary angioedema (HAE) by rapidly counteracting bradykinin‑mediated swelling.

Hereditary angioedema type I: provides rapid reduction of swelling, pain and associated airway obstruction during acute attacks, improving patient comfort and safety. Hereditary angioedema type II: delivers fast relief of edema and discomfort in attacks caused by dysfunctional C1‑inhibitor, helping to restore normal function. Acute hereditary angioedema attacks in adults: shortens the duration of episodes, reduces severity, and facilitates quicker return to daily activities.

Icatibant may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Injection site pain or erythema - Local swelling or induration at the injection site - Nausea or mild gastrointestinal discomfort - Headache or dizziness - Transient flushing - Fatigue or malaise

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Angioedema unrelated to HAE - Severe hypotension or shock - Thrombocytopenia or abnormal bleeding - Necrotic skin lesions at injection site - Acute respiratory distress

Before using Idanuz, consider the following safety measures. - Renal impairment: monitor renal function and adjust clinical observation as needed. - Hepatic disease: use with caution; assess liver enzymes regularly. - Pregnancy: limited clinical data; prescribe only if potential benefit outweighs risk. - Breastfeeding: unknown excretion in milk; evaluate risk versus benefit. - Concomitant ACE inhibitors or ARBs: may increase bradykinin levels; observe for enhanced edema. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Icatibant can interact with other medicines that affect the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may worsen angioedema. - Angiotensin receptor blockers: potential increase in vascular permeability. - Nitrates: may potentiate vasodilatory response leading to hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure and electrolytes. - Beta‑blockers: watch for exaggerated hypotensive episodes. - Other bradykinin antagonists: additive pharmacologic effect may increase risk of adverse events.